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Abstract  
Several cyclic peptides have been reported to have unexpectedly high membrane permeability. 
Of these, cyclosporin A is perhaps the most well-known example, particularly in light of its 
relatively high molecular weight. Observations that cyclosporin A changes conformation 
depending on its solvent environment led to the hypothesis that conformational dynamics is a 
prerequisite for its permeability; however, this hypothesis has been difficult to validate 
experimentally. Here, we use molecular dynamics simulations to explicitly determine the 
conformational behavior of cyclosporin A and other related cyclic peptides as they 
spontaneously transition between different environments, including through a lipid bilayer. 
These simulations are referenced against simulations in explicit water, chloroform, and 
cyclohexane and further validated against NMR experiments, measuring conformational 
exchange, nuclear spin relaxation, and 3D structures in membrane-mimicking environments, 
such as in DPC micelles, to build a comprehensive understanding of the role of dynamics. We 
find that conformational flexibility is a key determinant of the membrane permeability of 
cyclosporin A and similar membrane-permeable cyclic peptides, as conformationally constrained 
variants have limited movement into, then through and finally out of the membrane in silico. We 
envisage that a better understanding of dynamics might thus provide new opportunities to 
modulate peptide function and enhance their delivery.  
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Introduction 
Peptides are promising alternatives to small molecules as drug modalities, and are particularly 
attractive because of their potential applications in the ‘undruggable’ target space of intracellular 
protein:protein interactions,1 with several examples now available of peptides with promising 
activity profiles.2-5 However, a major challenge for peptides is their poor oral bioavailability, 
which limits their translation into drugs. 
 
Cyclosporin A stands in the face of this criticism: it is one of the largest known cyclic peptides to 
have pharmaceutically tractable oral bioavailability since the initial pharmacokinetic studies in 
which it was characterized 50 years ago.6 This 11-residue peptide (Figure 1) was originally 
isolated from the fungus Tolypocladium inflatum7,8 and is currently used as an 
immunosuppressant, modulating the expression of inflammatory cytokines by binding to the 
cytosolic protein, cyclophilin.9 After oral administration, cyclosporin A must cross the enterocyte 
layer of the gastrointestinal tract, enter the systematic circulation and subsequently make its way 
into the lymphocytes. As a peptide, the voyage from gut to cytosol faces several challenges, 
requiring passage across multiple cellular membranes. Cyclosporin A is thought to rely on 
passive diffusion to accomplish this feat.10,11 
 
Studies on peptide permeability12,13 suggest that the cyclic backbone and N-methyl moieties of 
cyclosporin A are partly responsible for its ability to diffuse across membranes. These structural 
characteristics lead to the burial of polar groups, presumably resulting in favorable desolvation 
energies for the transition from an aqueous to a membrane phase. These findings for cyclosporin 
have furthermore been more generally exploited to enhance the membrane permeability of other 
small cyclic peptides.14-16 Other recent studies have expanded the knowledgebase of membrane-
permeable cyclic peptides11 as well as our understanding of the determinants of peptide 
permeability, raising awareness of the importance of lipophilicity, structure, solubility, and size, 
as well as the interplay between these factors.17-22 
 
Conformational polymorphism is another feature of cyclosporin A thought to be important for its 
membrane permeability.11,23,24 This hypothesis is based on structural analyses of cyclosporin A 
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that showed a dependence of its structure and dynamics on the solution environment,10,25-29 as 
highlighted in Figure 1. In chloroform, cyclosporin A predominantly adopts a single 
conformation characterized by an elongated shape with internal hydrogen bonds that hide the 
constituent donor and acceptor groups from the solvent.25,26 Hereafter, we refer to this 
conformation as the “closed” state. Although cyclosporin A is thought to adopt multiple 
conformations in water,10 experimentally determined structures in water are not available. 
Alternative structures to that formed in chloroform have been elucidated but these are of 
cyclosporin A bound to a protein target, typically cyclophilin.30-32 Nevertheless, these structures 
provide the most reasonable representation of a non-chloroform, and potentially aqueous, state; 
we refer to these as the “open” conformations because of the increased exposure of the polar 
groups.  
 
The hypothesis that conformational change (and so dynamics) of cyclosporin A facilitates its 
diffusion across membranes is easy to conceptualize but difficult to test experimentally because 
chemical modification to preference a particular conformation or tune structural rigidity would 
invariably change peptide lipophilicity and size, making it difficult to delineate the contribution 
of conformational flexibility. Predicted structures of cyclic peptides in implicit solvents of low 
and high dielectric constants that approximate aqueous and lipid environments, respectively, 
have been shown to be predictive of the propensity for membrane insertion.23,24 Instead of 
focusing on defined time-points during the permeation process, molecular dynamics offers a way 
to explicitly track conformational motion, resolving spatial and temporal dimensions as the 
peptide permeates through the membrane and in response to variations in simulation parameters, 
such as temperature.33,34 Several studies have examined the behavior of cyclosporin A in water 
and chloroform in silico.35-38 Early attempts were limited by their short simulation times (in the 
ps range),35-37 but more recent studies have shown the potential of extended simulations in these 
solvents to capture the landscape of conformations and inter-conversion rates between 
conformations, which can be used to rationalize differences in permeability.38,39 Here we extend 
these studies to new ground to look explicitly at the transition between different environments, 
such as aqueous and lipid phases.  
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In the current study our aim was to understand the contribution of dynamics to the membrane 
permeability of cyclic peptides. To build towards that goal, we first simulated cyclosporin A in 
simple solvents to validate the simulation parameters against NMR-derived data, and then moved 
to more complex systems that more accurately mimic cellular membranes, demonstrating the 
role of conformational flexibility in membrane permeability. Finally, we broadened the study to 
examine other membrane-permeable cyclic peptides. A better understanding of the membrane 
permeability of cyclic peptides might facilitate the future design of membrane-permeable and 
orally bioavailable peptides. 
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Methods 
Chemicals and peptides 
Deuterated acetonitrile (acetonitrile-d3, 99.8%), chloroform (chloroform-d, 99.8%, with 0.03% 
v/v tetramethylsilane), cyclohexane (cyclohexane-d12, 99.5%), and dodecylphosphocholine 
(dodecylphosphocholine-d38, 98%) were purchased from Novachem. Cyclosporin A (≥98.5%) 
was purchased from Sigma Aldrich. Cyclosporin H (≥95%) was purchased from Cayman 
Chemicals. 
 
NMR spectroscopy 
NMR samples were prepared by dissolving dried peptide (1 mg) in 550 μL of the desired solvent 
mixture; i.e., 38–100% (v/v) acetonitrile-d3 (mixed with water), pure chloroform-d, pure 
cyclohexane-d12, or a mixture of dodecylphosphocholine-d38 with water. Typically, samples 
were centrifuged at 13,000 rpm for 10 min to remove precipitate (which was observed for the 
cyclohexane sample) before data acquisition. One- and two-dimensional NMR spectra (1H, 1H 
TOCSY, NOESY) were recorded on a Bruker Avance 500 MHz spectrometer at the indicated 
temperatures. Mixing times of 80 and 200 ms were used for TOCSY and NOESY experiments, 
respectively. Spectra were processed with TopSpin (Bruker), phased and calibrated, and then 
assigned with CCPNMR software v2.4.2.40 Chemical shifts in the 1H dimension were referenced 
to internal 4,4-dimethyl-4-silapentane-1-sulfate or tetramethylsilane.  
 
Relaxation measurements were carried out using Bruker Avance 500, 600, and 900 MHz 
spectrometers, as previously described.41 T1 (spin-lattice) 13C relaxation times were measured 
using the Bruker pulse program hsqct1etgpsi3d.2. NMR spectra were acquired with a spectral 
width of 14 ppm over 2048 complex points in the 1H dimension, and 12 ppm over 40 complex 
points in the 13C dimension. To determine T1 values, 12 relaxation delays in the range of 0.01 to 
2.5 s were used. A recycle delay of 2 s was used. Peak heights were measured in CCPNMR and 
fitted using a two-parameter fit exponential equation to determine T1 values. Experiments were 
carried out in triplicate, with a different order of relaxation delays used in each experiment; the 
mean and standard deviation for the T1 values were derived. 
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13C NOEs were determined from the ratio of peak intensities from 2D 1H–13C correlation spectra 
measured via double inept transfer using sensitivity improvement with decoupling during 
acquisition, using Bruker pulse program hsqcnoegpsi.2. A recycle delays of 2 s was used. NOE 
on and NOE off spectra were processed with a zero scaling factor, phased identically, and the 
intensities of the respective peaks were measured using CCPNMR software. Errors were 
calculated as the standard deviation over triplicate measurements. 
 
The relaxation data were fitted to equations described in the model-free formalism using the 
‘Solver’ function in Microsoft Excel, as previously described.41 Errors were estimated by fitting 
to simulated data generated using a Monte Carlo algorithm. The fits of the NOE values were 
given a 50% weighting compared to the T1 values, to take into account the higher uncertainty in 
the experimental NOE measurements.41 
 
Molecular dynamics 
The solid-state structure of cyclosporin A crystallized from chloroform was used as the “closed” 
form (CCDC code: DEKSAN), whereas the solution-state structure bound to cyclophilin was 
used as the “open” form (PDB ID: 1CYA). The open form was selected by downloading, 
aligning, and visually inspecting structures of cyclosporin A (and its analogues) deposited in 
PDB (35 in total; i.e., 1BCK, 1C5F, 1CSA, 1CWA, 1CWB, 1CWC, 1CWF, 1CWH, 1CWI, 
1CWJ, 1CWK, 1CWL, 1CWM, 1CWO, 1CYA, 1CYB, 1CYN, 1IKF, 1M63, 1MIK, 1QNG, 
1QNH, 1XQ7, 2ESL, 2OJU, 2POY, 2RMA, 2RMB, 2RMC, 2WFJ, 2X7K, 2Z6W, 3BO7, 3CYS, 
3EOV). The solid-state structure of cyclosporin H crystallized from methanol42 was used as the 
starting conformation in simulations. The solution structure of cyclic peptide 13 was used in our 
simulations;16 the structure of cyclic peptide 1 was derived from cyclic peptide 13 by removing 
the N-methyl groups in silico. 
 
Force field parameters for the peptides were derived from the CHARMM27 force field. For non-
standard amino acids, parameters for their side-chains were obtained from SwissParam 
(http://www.swissparam.ch/); parameters for their backbone regions were initially derived from 
the CHARMM27 force field, and later modified as described. Force field parameters for 
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chloroform were based on the rigid model of Dietz and Heinzinger43 (which was previously 
shown to reproduce experimental liquid properties44), parameters for cyclohexane were obtained 
from a CHARMM force field for ethers, and parameters for POPC were extracted from the 
CHARMM36 force field (which has been optimized for lipids).  
 
Simulation protocols were modified from previously described methods for cyclic peptides in 
explicit solvent.41,45 Specifically, for simulations in a single solvent (i.e., chloroform, water, or 
cyclohexane only), a cubic box of solvent (50 × 50 × 50 Å) was constructed and the peptide was 
placed at the center. For simulations using a biphasic system (i.e., chloroform and water), a box 
(80 × 80 × 100 Å) filled with chloroform in the lower half and water in the upper half was 
constructed, and the peptide was placed at the center of the water partition. With harmonic 
restraints of 5 kcal/(mol Å) on the centroid of the Cα atoms and dihedral angles of cyclosporin 
A, each system was first minimized with 10,000 steps of conjugate gradient energy minimization 
using NAMD v2.11. This was followed by a 100-ps simulation in the canonical (NVT) ensemble 
and then 100 ps isothermal-isobaric ensemble (NPT) simulation at the experimental temperature 
and pressure, both with the harmonic restraints. A further equilibration of 1 ns was conducted 
before initiating production runs. The harmonic restraints on the dihedral angles were maintained 
for simulations of the constrained closed and open conformations, or were removed otherwise. 
Molecular dynamics simulations were performed using periodic boundary conditions. The 
particle mesh Ewald method with a real space cutoff of 12 Å was used to treat Coulomb 
interactions and a force-switching function was applied to smooth Lennard-Jones interactions 
over the range of 10–12 Å. All covalent hydrogen bonds were constrained by the SHAKE 
algorithm (or the SETTLE algorithm for water), permitting an integration time step of 2 fs. 
Coordinates were saved every 100 ps. 
 
For simulations in a lipid/water system, a box (80 × 80 × 100 Å) was constructed, comprised of a 
POPC (1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine) lipid bilayer and the peptide placed in 
the aqueous phase. With harmonic restraints of 2 kcal/(mol Å) on all non-hydrogen atoms and 5 
kcal/(mol Å) on all peptide dihedral angles, the system was first subjected to 10,000 steps of 
conjugate gradient minimization, followed by 490-ps NPT simulation. A Langevin thermostat 
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with a damping coefficient of 1 ps-1 was used to maintain the system temperature. The system 
pressure was maintained at 1 atm using a Langevin piston barostat. Initially, covalent hydrogen 
bonds were not constrained and an integration time step of 1 fs was used. Then, a 1.5-ns 
simulation was carried out with harmonic restraints of 2 kcal/(mol Å) on all heavy atoms, while 
maintaining harmonic restraints on peptide dihedral angles. Afterwards, all covalent hydrogen 
bonds were constrained by the SHAKE algorithm (or the SETTLE algorithm for water) and the 
integration time step was increased to 2 fs for a 4-ns simulation, while restraining all heavy 
atoms and peptide dihedral angles. Then, a 9-ns simulation with harmonic restraints of 2 
kcal/(mol Å) on all peptide carbon atoms and 5 kcal/(mol Å) on all peptide dihedral angles and 2 
kcal/(mol Å) on C1 carbon of all POPC lipids was carried out. Subsequently, restraints on the 
carbon atoms were removed for simulations of the constrained, closed and open conformations, 
and the system was equilibrated for a further 3 ns before carrying out production runs. 
Otherwise, all restraints were subsequently removed, and the system was equilibrated for 3 ns 
before production runs were conducted using ACEMD v1.6.0. Compared to simulations using 
NAMD v2.11, the cutoff was changed to 9 Å, and the integration time step was increased to 4 fs 
with the use of hydrogen mass re-partitioning as implemented in ACEMD.  
 
Order parameters were calculated from the simulations by overlaying all snapshots from the 
trajectories to the structure of the first snapshot, as previously described.41,46 The approach has its 
limitations (e.g., it is sensitive to the quality of the structural alignments), but is useful for 
providing broad indications on the flexibility of the system being studied. For each snapshot, the 
unit vector along the Cα-Hα vector was obtained from its Cartesian co-ordinates and used in the 
following equation: 
    
, where ‹› denotes the average over all snapshots from the trajectory. 
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Results 
Dynamics of cyclosporin A 
We confirmed that the conformation is dependent on solution environment in a series of NMR 
studies of cyclosporin A in a range of solvent mixtures (Figure 2a). Cyclosporin A is sparingly 
soluble in water and thus we used deuterated acetonitrile/water mixtures in a first set of 
experiments to confirm the role of the solvent. In a predominantly aqueous environment (<40% 
CD3CN content), the large number of peaks in the 1H 1D NMR spectrum indicates the presence 
of at least three conformations in slow exchange on the µs-ms timescale. In general, increasing 
the acetonitrile concentration increases structural homogeneity as judged by a reduced number of 
spectral peaks. Indeed, the spectrum of cyclosporin A in pure acetonitrile indicates convergence 
to one major conformation (population >90%), consistent with previous findings.28 
  
The conformational homogeneity is even greater in pure chloroform, where the spectrum is 
dominated by just four peaks in the amide region of the spectrum–corresponding to the four 
backbone amides of cyclosporin A, and indicating one major conformation is present. This 
conformation is well characterized and is shown in Figure 1. A minor conformation (population  
<6%) has been reported and differs from the major conformation by cis/trans isomerization 
about an N-methylated peptide bond.26 Overall the data suggest minimal conformational 
dynamics on the ms timescale (as assessed by NMR peak analysis) in chloroform. But what 
about faster motions not detected based on peak multiplicity? 
 
We used NMR relaxation measurements to gain a more precise understanding of the backbone 
dynamics on the ns-timescale of cyclosporin A in chloroform (Figure 2b). 13C NMR spin-lattice 
(T1) relaxation times and heteronuclear NOEs (hNOEs) for the Cα-Hα bonds were recorded at 
three field strengths (i.e., 500, 600, and 900 MHz) and interpreted according to the model-free 
formalism,47 which provides values for the correlation time (reflecting the rate of rotational 
diffusion) and the order parameters (reflecting the amplitudes of local motions). For cyclosporin 
A in chloroform the overall correlation time was found to be 0.28 ns, with order parameters (S2) 
for individual backbone Cα sites ranging from 0.72 to 0.83 (mean of 0.78). This result is 
consistent with a partial analysis of backbone Cα dynamics reported earlier,48 apart from two 
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outliers in that analysis that gave very low order parameters. The important conclusion to arise 
from this analysis is that individual backbone sites of cyclosporin A do have limited amplitude 
fast (sub ns-timescale) motions and this peptide is more flexible than other cyclic peptides with 
highly cross-braced structures, which typically exhibit S2 values >0.8.41,49 In other words, in any 
given conformation cyclosporin A is not completely rigid (S2 values ~1.0 would be expected for 
a rigid molecule). These experimental solution state data provide a benchmark upon which to 
calibrate in silico simulations, as detailed below. 
 
Simulations of the closed structure of cyclosporin A in chloroform 
Since it is well established that the closed form of cyclosporin A is the main conformation in 
chloroform we explored whether this structure can be faithfully predicted in silico. Accordingly, 
a model of the closed form was placed in a box of explicit chloroform and subjected to molecular 
dynamics simulations. Over the course of the simulation runs at both 298 and 315 K, very little 
deviation from the starting structure was observed (Figure 3a). Increasing the temperature to 490 
K resulted in increased local flexibility, as well as sporadic and significant deviations from the 
closed structure; however, the closed form was still the most frequently observed over the 
simulated time (Figures 3a and 3b).  
 
We compared the order parameters calculated from the simulations to experimentally determined 
values and found that elevated temperature simulations better recreated the experimentally 
observed dynamics than the room temperature simulations (Figure 3c). Order parameters were 
calculated from the simulations by integrating the time-dependent fluctuations of the Cα-Hα 
bond vectors using a previously described approach.46 Despite its limitations, the approach is 
suitable here because the simulation times are long relative to the experimentally determined 
rotational correlation time of cyclosporin A (i.e. ~0.3 ns) and also the magnitude of structural 
deviations is small. As shown in Figure 3c, simulations at 298 and 315 K overestimate the 
rigidity of cyclosporin A; at 490 K, there is better agreement with the results of the NMR spin 
relaxation analysis. The force field parameters acting on the system at lower temperatures appear 
to be too restrictive, but this restriction is compensated by increasing the simulation temperature 
so that the NMR-observed behavior can be better replicated in silico. Effectively the high 
12 
 
temperature simulations provide sufficient energy to fast-track the simulations so that dynamics 
trends can be predicted in a reasonable timeframe and without significantly affecting the 
thermodynamics of the system.34,50 Note that there is no inference that the 490K temperature 
would ever be reached (or relevant) in a biological system. 
 
Simulations of the open structure of cyclosporin A in chloroform 
We attempted to simulate conversion of the open to closed form in chloroform, but this structural 
conversion was initially difficult to simulate (Figure 4a). We conducted molecular dynamics 
simulations of the open structure in an explicit chloroform box, but conversion was not observed 
over the simulated time at 315 K. A higher temperature simulation was better able to induce 
conversion, giving conformations that were similar to the closed form. These closed form-like 
conformations differed from the closed conformation mainly by the geometry of the Mle-3 
peptide bond, i.e., they were in the trans, rather than cis, orientation (Figure 4a). Based on this 
observation, we speculated that the force field parameters acting on the ω-bond angle are overly 
constraining, so we investigated whether the force field could be modified to allow for cis/trans 
inter-conversion. 
 
We carried out atomic biased force calculations to explore the effect of the peptide bond 
parameters on the ω-dihedral free energy landscape of a model system comprising a N- and C-
capped amino acid and found the cis/trans transition energies could be reduced by decreasing the 
appropriate force constants (Figure 4b). Specifically, a capped Ala residue was subjected to 2.5 
ns and 25 ns simulations, both of which had similar energy profiles, suggesting convergence in 
sampling was obtained. Addition of a methyl group at the amide position, without modifying the 
force field parameters for the remainder of the amino acid, resulted in an 18% reduction in the 
transition energy barrier, as well as a 60% reduction in the free energy of the cis state. This result 
is consistent with quantum mechanical calculations on the effect of N-methylation on cis/trans 
conversion of Ac-X-OMe amino acids, reporting an average drop of 80% in the energy 
difference between the cis–trans conformations after N-substitution.51 Lowering of the force 
constant of the parameters acting on the ω-dihedral angle in the force field to 80% and then 60% 
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of the original values resulted in further reductions of the transition free energy, yet maintained 
the free energy level of the cis state.  
 
By incorporating the modified force field tested in the model Ala system into a full simulation 
for cyclosporin A we identified conditions in which the open structure converted to the closed 
structure in chloroform (Figure 4c). Initially, reduction of the force constants to 80% of their 
original values did not improve sampling of the closed structure at 490 K. However, a further 
reduction of the force constants, to 60% of their original values, improved sampling (Figure 4c). 
Interconversion between the open and closed structures was observed using the modified force 
field at 448 K, but not at 315 or 393 K (Figure 4d). Although the closed structure was 
successfully regenerated from the open structure at both 448 and 490 K, the closed structure did 
not remain stable for the entire simulation (Figures 4c and d); this is not unexpected as 
cyclosporin A exchanges between a major and minor conformation in chloroform (Figure 2a) 
probably due to cis/trans isomerization26 as noted above. Modifying only the force field 
parameters that act on the Mle-3 ω-angle resulted not only in the occurrence of the closed 
structure, but also in increased structural stability of the closed form (Figure 4d). Overall, the 
results show that the original force field imposed energetic penalties that inhibited complete 
conversion of the open to the closed structure within the simulation times. Increasing the 
temperature and relaxation of the force constants facilitated formation of the closed structure.  
 
Simulations of the open and closed forms of cyclosporin A in water 
NMR studies of cyclosporin A indicate that it adopts multiple conformations in water,10 and we 
found that this behavior could be replicated in silico. In a box of explicit water, significant 
deviations from the starting structure, either closed or open, were observed at 315 and 490 K 
(Figure 5a). The higher temperature simulations were better able to produce the expected 
behavior because of the transition of the Mle-3 peptide bond from the cis to trans orientation. As 
shown in Figure 5b, the water environment leads to conformations that have larger solvent-
accessible surface areas and more open polar groups than in chloroform. Overall, the simulations 
in water provide additional support that the modified force field and higher temperatures 
appropriately replicate experimental cyclosporin’s conformational behavior. 
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Simulating the transition from water to chloroform 
Since the focus of this study is the transition of cyclosporin A between different solvent phases, 
we simulated the peptide in a biphasic system and found that it readily partitioned into the 
chloroform phase (Figure 6a). Due to its high lipophilicity, cyclosporin A favors the apolar phase 
of a polar-apolar biphasic system, with log P values of 2–3 in octanol/heptane36 or 
octanol/isooctane10 mixtures. We constructed a simulation box comprising an explicit water 
phase and an explicit chloroform phase and then positioned the open structure of cyclosporin A 
in the center of the aqueous partition. Cyclosporin A moved rapidly into the chloroform partition 
and then remained just under the chloroform–water interface for the remainder of the simulation. 
Cyclosporin A adopted the closed conformation during transition from the upper chloroform-
water interface to the lower interface (Figure 6a). We speculated that it was unable to move back 
through the chloroform phase into the upper interface in the simulation because the interfacial 
environment did not encourage formation of the closed structure. Indeed, when cyclosporin A 
was constrained into the closed form, it diffused through the chloroform phase with higher 
frequency (Figure 6b). On the other hand, when constrained into the open form, it was unable to 
transition through the chloroform phase and was trapped at the upper water–chloroform interface 
(Figure 6b). These simulations support the importance of conformational change for the 
movement of cyclosporin A between different solvent environments. 
 
NMR structural studies of cyclosporin A in membrane mimics 
We next altered our focus from chloroform to systems that mimic the membrane environment, 
and demonstrated that the closed conformation or one similar to that exists in lipids (Figure 7a). 
We considered cyclohexane because of the abundance of CH2 groups in both cyclohexane and 
lipid tails. Additionally, the force field parameters for cyclohexane and lipid tails have many 
similarities, allowing for more meaningful comparisons between experiment and simulation. We 
also examined dodecylphosphocholine (DPC) because of its structural similarity to POPC; 
another approach is to use bicelles. The structure of cyclosporin A in SDS has been previously 
reported.29 As shown in Figure 7a, the Hα chemical shifts show a similar trend across the 
sequence of cyclosporin A in chloroform, cyclohexane, SDS,29 and DPC, with those in 
15 
 
cyclohexane and chloroform being most similar. Notably, there are some differences in chemical 
shifts (Figure 7a); for example, Sar-7 exhibits an Hα chemical shift in the presence of DPC that 
is 0.26 ppm downfield to that in chloroform, which might indicate differences in the local 
backbone geometry. Therefore, the analysis of Hα chemical shifts suggest that the 
conformational behavior of cyclosporin A in DPC is not identical to that in chloroform but could 
also have similarities.  
 
Figure 7b shows that cyclosporin A adopts a single conformation (or multiple conformations in 
fast exchange) in cyclohexane. The 1H 1D spectrum at 288 K (and other temperatures) exhibits 
four sharp peaks in the amide region that correspond to the four backbone amides, resembling 
the behavior in chloroform (Figure 2). By comparison, there is greater conformational 
heterogeneity in the presence of DPC because of the presence of slow-exchanging conformations 
in addition to the major conformer. The distribution of these peaks in the 1H 1D spectrum as well 
as the Hα chemical shifts of the main conformer did not change significantly as the cyclosporin 
to DPC ratio was increased from 1:50 to 1:100 (Supplementary Table S1, Supplementary Figures 
S1–S4). Despite these differences in the 1H 1D spectrum between chloroform and DPC, 
preliminary structures of cyclosporin A at 1:50 and 1:100 peptide to DPC ratios calculated using 
NOE restraints (Supplementary Tables S2 and S3, Supplementary Figures S5 and S6) indicate 
that the structure in DPC could resemble the closed conformation, although there might be 
differences in the backbone geometry, for example at Sar-7 and Ala-11 (Supplementary Figure 
S7). Similarity in the general trend in temperature coefficients and 3JHN-Hα constants 
(Supplementary Table S4) with the presence of localized differences (e.g. Ala-11 having ~1 Hz 
3JHN-Hα difference between cyclohexane and DPC) supports this conclusion. Although the 
structures could be further refined, the data generally show that the closed form could exist in a 
lipid bilayer.  
 
 
Simulations of cyclosporin A in cyclohexane 
We next showed that cyclosporin A could adopt the closed structure in cyclohexane in silico 
(Figure 8a). We placed the open form of cyclosporin A in a box of explicit cyclohexane and 
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carried out molecular dynamics simulations. At 315 K, the simulated structures did not approach 
the closed form, but increasing the temperature improved sampling of the closed structure. At 
448 K, for example, the open structure rapidly converted to the closed form and remained stable 
in the closed structure. A further increase in temperature to 490 K resulted in sampling of 
additional non-closed structures, so 448 K was the optimal simulation temperature. 
 
Simulations of cyclosporin A with a lipid bilayer 
Having characterized the behavior of cyclosporin A in various solvent environments and with 
different simulation parameters, we conducted simulations of cyclosporin A in the presence of a 
lipid bilayer, and found that conformational dynamics is an important determinant of 
permeability (Figure 8b–f). A simulation box comprising a POPC lipid bilayer patch and the 
open structure of cyclosporin A positioned above the patch was constructed. Early in the 
simulation, cyclosporin A partitioned into the lipid bilayer (Figure 8b). We experimentally 
confirmed that cyclosporin A can bind to a POPC lipid bilayer using SPR with the bilayer 
deposited on a L1 sensor chip, as shown in Supplementary Figure S8. Over the course of the 
simulation, cyclosporin A moved through the lipid bilayer while adopting various conformations, 
including the closed form. Solid-state NMR and small angle X-ray diffraction experiments have 
previously shown that cyclosporin A can reside in the membrane interior.52 Figure 8c shows that 
the closed form is preferred when cyclosporin A is sequestered near the lipid tails where there is 
low exposure to water, but becomes less preferred as cyclosporin A moves away from the 
membrane core and becomes more open to water.  
 
We then examined the effect of temperature on the translational properties of cyclosporin A in 
silico (Figure 8d). At 315 K, cyclosporin A remains in the aqueous phase. At 393 K, it enters the 
membrane but is stuck in the upper leaflet of the bilayer. At both 315 and 393 K, the closed 
structure is never observed. At 490 K, cyclosporin A is again able to move through the lipid 
bilayer, but the movement is more rapid and the occurrence of the closed structure is less 
frequent compared to the simulation at 448 K. A change in the simulation temperature also 
affects the lipid bilayer. Figure 8e shows that an increase in temperature results in thinning of the 
bilayer, as indicated by increases in the area per lipid. Thus, the ability of cyclosporin A to move 
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through the bilayer could be due to the ability of the simulated structures to adopt the closed 
form and/or porosity of the lipid bilayer.  
 
To explore whether the conformation of cyclosporin A is indeed a determinant of its membrane 
permeability in the presence of a thinned bilayer, simulations of cyclosporin A constrained in 
either the closed form or the open form were carried out and compared to simulations without 
constraints. As shown in Figure 8f, when cyclosporin A is not constrained, its distance from the 
membrane center is distributed along the normal of the bilayer. When cyclosporin A is 
constrained in the closed form, the distance distribution is narrower because it predominantly 
stays in a lipid core surrounded by lipid tails. When cyclosporin A is constrained in the open 
conformation, it is unable to permeate the membrane and remains trapped in the upper leaflet. 
Overall, the simulations of cyclosporin A, either unconstrained or constrained, show that 
conformational flexibility is important for the membrane permeability of cyclosporin A.  
 
Extension to simulations of cyclosporin H and other cyclic hexapeptides in a lipid bilayer 
To provide further validation and to broaden the study, we conducted simulations of other cyclic 
peptides, including cyclosporin H (Figure 9a) and two cyclic hexapeptides (Figure 9b), in the 
presence of a lipid bilayer, and confirmed that conformational flexibility can indeed affect 
movement through a membrane. Cyclosporin H is able to passively diffuse across an artificial 
membrane, but is less permeable than cyclosporin A (i.e. log(Pe) of -5.36 compared to -5.01).11 It 
differs from cyclosporin A by a stereochemical inversion at residue 4, but like cyclosporin A, it 
also exhibits solvent-dependent conformational change (Figure 9a). Its solid-state structure has 
been determined from methanol-grown crystals (Figure 9a);42 however, the structure is different 
to those reported for cyclosporin A (Figure 1), and so provides a different starting point for our 
in silico investigations. As shown in Figure 9c, when cyclosporin H starts (unconstrained) in this 
conformation in the presence of a membrane, it enters the membrane and transitions to the other 
side, sampling different locations along the membrane normal during the simulation, including 
the membrane core and the outer aqueous compartment. By comparison, when constrained in 
this starting conformation, cyclosporin H rapidly partitions into the membrane, but does not 
sample as diverse a range of locations. A similar dependence of positional distribution on 
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conformational restriction is also exhibited by a cyclic hexapeptide (i.e. cyclic peptide 13) that 
we have previously shown to have high passive membrane permeability and oral bioavailability 
(i.e., F = 33% when administered orally in rats).16 The unconstrained peptide moves more freely 
through the membrane than its constrained form or a non-N-methylated variant (i.e. cyclic 
peptide 1, which was first reported as compound 424) reported to have lower permeability.16 
Overall, the simulation results clearly demonstrate that conformational flexibility can help 
mediate passive transport across membranes.  
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Discussion 
Here we studied how conformational dynamics affects the passage of peptides across biological 
membranes. We focused on cyclosporin A, a peptide drug that has high membrane permeability 
for its size.19 Its conformational flexibility has been hypothesized to be a key determinant of its 
ability to cross membranes.11,23,24 This hypothesis has been difficult to study, particularly at the 
molecular level, because the factors that affect permeability are multifarious and many 
biophysical techniques lack the spatial and temporal resolution needed. Thus, we explored the 
potential of molecular dynamics, alongside NMR, to characterize the dynamics of cyclosporin A 
and other membrane permeable cyclic peptides, and their spontaneous partitioning into and out 
of lipid membranes.  
 
Studying membrane permeability of cyclosporin A using molecular dynamics is challenging 
because membrane diffusion and conformational change, including cis–trans bond transitions,  
occur on slow timescales. Specifically, based on an apparent permeability of ~10-5 cm/s,11 the 
rate at which cyclosporine A crosses a lipid bilayer would be ~10 s-1. Compared to this, cis–trans 
rotation about the Mle-2 peptide bond is slower in an aqueous-like environment (i.e. ~10-3 s-1 in 
pure tetrahydrofuran53). In chloroform, the interconversion rate increases by up to 1000-fold, 
with a cis to trans conversion rate of ~10-2 s-1 and trans to cis conversion of 1 s-1; these rates 
further increase with increasing temperature.54 Clearly, the timescale of these processes require 
substantial computational resources and/or advanced sampling techniques for exhaustive 
characterization. Indeed, previous molecular dynamics simulations have been too short (i.e., 50 
ps–2.1 ns) to observe conformational changes at ambient temperatures without adding biased 
restraints.35,37 Longer simulations (i.e., 100 ns seeded simulations; 10 μs total) at near ambient 
temperatures have demonstrated more success in obtaining convergence, showing that expected 
behavior (e.g., cis-trans bond populations) can be simulated.38  
 
Our approach was to perform simulations using a wide range of conditions (i.e, at a range of 
temperatures, in a range of solvents, using a range of structural parameters), and to interpret the 
results with reference to NMR data. As in previous simulations, elevated temperatures were used 
to accelerate sampling.33,34,37 The use of high temperatures in simulations is now widespread, and 
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has proved valuable to study peptide–membrane interactions. For example, the partitioning and 
transmembrane insertion of helical polyleucine segments have been studied at 353-490 K, which 
directly revealed all states populated at equilibrium.33 Here, we demonstrated that elevated 
temperatures indeed improved sampling and produced better agreement with experimental 
results compared to lower temperature simulations. For example, elevated temperature 
simulations of the open structure in either chloroform or cyclohexane facilitated conversion into 
the closed form, consistent with experimental observations (Figures 1 and 7b). Furthermore, 
there was a higher degree of structural deviation in chloroform compared to cyclohexane, again 
confirmed by experimental data (Figures 1 and 7b). As well as elevated temperatures, which 
facilitates peptide bond isomerization in silico,55 modification of the force field parameters 
acting on the ω-angle of N-methylated residues also assisted in improving sampling (Figure 4c). 
Nevertheless, the requirement of higher temperatures and force field modifications suggest that 
large energy barriers restrict sampling in the system studied here. With modifications to the 
simulation parameters, we confirmed the dependence of conformation on the solvent observed 
experimentally.10,25-29 By performing simulations in simple solvent systems first, we established 
a foundation for studying cyclosporin A in the presence of lipid bilayers.  
 
Cyclosporin A permeates membranes in in vitro trans-well assays,10,11 confirming that passive 
diffusion across membranes is an important step towards achieving cell permeability and oral 
absorption. We aimed to address the question of whether conformational flexibility is important 
for this membrane permeability. The observation that unconstrained cyclosporin A can move 
more freely in a water–chloroform biphasic system than can either the constrained closed or open 
structures provided initial evidence in support of the importance of dynamics (Figure 6b). 
Further support came from simulations in the presence of a lipid bilayer (Figure 8f). 
Unconstrained cyclosporin A moved more freely in a lipid bilayer than constrained cyclosporin 
A, which was predominantly trapped in the membrane core or interface depending, on whether it 
was in the closed or open structure, respectively. Additionally, this dependence of movement 
through a lipid bilayer on conformational flexibility was observed for other cyclic peptides 
reported to be membrane permeable (Figure 9). If complete rigidity can limit permeability, does 
this mean that flexibility is the key? To a degree. Increased flexibility, for example as would 
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occur by linearizing cyclosporin A, would be expected to decrease permeability because the 
linear peptide would be less able to sample the conformation favorable for membrane insertion.  
 
Conformational polymorphism affects all stages of the membrane permeability of cyclosporin A 
(Figure 10). To permeate membranes, cyclosporin A must transition from an aqueous 
environment into the chemically-opposing environment of the membrane core. Based on studies 
of membrane permeability of peptides,19,20,56 many factors are thought to affect this transition, 
including electrostatic contributions, non-polar contributions, and lipid perturbation effects, in 
addition to peptide conformational effects. In the aqueous phase, cyclosporin A samples multiple 
conformations as evidenced by 1D 1H NMR spectra in polar solvents and water.10,27 In water, 
both closed and open conformations are not stable in silico; however, these starting 
conformations may still exist sporadically, as previously suggested.38 Some of the conformations 
sampled in water are more favorable than others for insertion into as well as movement through 
the membrane. For example, although both the closed and open form can partition to the 
membrane in silico, only the closed form can more freely move through the membrane; the open 
form prefers to sit at the water–membrane interface (Figure 8). The inter-conversion rates 
between conformations that favor and disfavor membrane permeability are thought to drive 
permeability, particularly when the time scales of conversion are slower than permeation.39 
 
On average, insertion of cyclosporin A into a lipid membrane is an endothermic process, 
governed by an enthalpic penalty that is counterbalanced by favorable entropic changes.52 The 
enthalpic contribution to insertion might be brought about by: (i) a reordering of water molecules 
about the peptide surface; (ii) changes in hydrogen bonding between water and cyclosporin A; 
or, (iii) a combination of both processes. Evidence of multiple conformations of cyclosporin A, 
in which some have smaller polar surface areas or have their backbone polar groups more 
protected from the solvent, supports the role of conformational change in facilitating insertion. 
Additionally, some conformations of cyclosporin A have larger non-polar surface areas, which 
would facilitate insertion via the classical hydrophobic effect, which is an entropy-driven 
phenomenon. Both electrostatic and non-polar contributions add to the overall desolvation 
energy, which has been suggested to be a predictor of membrane permeability.12,23  
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Upon insertion into a membrane, cyclosporin A can partition into the membrane core.52,57 Based 
on structural studies in chloroform (a solvent with a low dielectric constant that mimics the 
membrane core), cyclosporin A is commonly assumed to adopt the closed structure inside the 
membrane. We showed using a NMR relaxation analysis that cyclosporine A exhibits limited 
amplitude fast backbone motion; we hypothesize that the lack of absolute rigidity is important to 
enable structural change. We further demonstrated that cyclosporin A can indeed form the closed 
form in environments that mimic the membrane (Figure 7a); for example, the Hα chemical shifts 
of cyclosporin A in cyclohexane are almost identical to those in chloroform. In the presence of 
DPC, the chemical shifts are, generally, similar to those in cyclohexane and chloroform, 
suggesting that the overall structure in the micelle environment resembles the closed form. This 
conclusion is supported by a comparison of temperature-dependent amide proton shifts (markers 
of solvent exposure and hydrogen bonding) in cyclohexane with those in the presence of DPC. 
We demonstrated that the closed structure favored the membrane interior when cyclosporin A 
was constrained during simulations in the presence of a lipid bilayer (Figure 8f). However, when 
cyclosporin A was not constrained, alternative conformations were observed in the membrane 
core. Conformational flexibility might be beneficial inside the membrane because it might 
reduce the entropic cost of insertion. It also increases sampling of positions along the membrane 
normal (Figure 8f), suggesting that it might also facilitate departure of cyclosporin A from the 
membrane interior, as was observed for cyclosporin H and cyclic peptide 13 (Figure 9c).  
 
It is also thought that lipid perturbation effects can affect membrane insertion of peptides. Lipid 
perturbation effects arise from conformational dynamics of the lipid chains in the bilayer and are 
dependent on the size of the inserted peptide. We observed that changes in the conformation of 
cyclosporin A resulted in changes in the overall size, with the closed conformation being 
generally smaller than those found in water (Figure 5b). Peptide size also affects diffusion of a 
peptide through a membrane, as corroborated in a recent study of a range of cyclic peptides.19 As 
that study noted, as did an earlier study,58 diffusion through a membrane is in accord with a 
polymer-based model rather than a Stokes-Einstein model. In the polymer model, peptides move 
through the membrane by successively occupying nearby voids that sporadically appear. This 
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might explain the observation that insertion is favored in elevated temperature simulations, in 
which the membrane is less compact (Figure 8). Interestingly, the polymer-model predicts that 
the diffusion rate correlates with the short dimension of the diffusant; this is consistent with the 
closed conformation being favorable for membrane permeation because it resembles an 
elongated shape with one dimension shorter than the other (Figure 1). If the polymer model is 
more appropriate for representing membrane permeability, then simulations in the presence of a 
lipid bilayer should have broad utility for studying peptide permeability.  
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Conclusions 
In summary, we have used simulations to provide a molecular microscope to monitor the 
dynamics of membrane-permeable cyclic peptides and its role in membrane permeability. We 
found that conformational polymorphism is indeed an important feature of these peptides, 
allowing them to more readily move through a lipid bilayer. Given that increasing attention is 
being paid to exploring the potential of peptides as therapeutics, there is a greater need to 
understand how peptides can permeate membranes, leading to a better understanding of how 
peptides might be modified so that they can be delivered orally.  
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Figure Legends 
Figure 1. Cyclosporin A, open and closed structures, and the question of membrane 
permeability. The sequence and chemical structure of cyclosporin A is shown at the top right, 
with each residue labelled with its three-letter code. Residues 1, 5, and 10 are labelled with the 
residue number. Cyclosporin A has seven N-methylated amino acids (i.e., Mle-2, Mle-3, Mva-4, 
Bmt-5, Sar-7, Mle-8, and Mle-10) and four non-N-methylated amino acids (i.e., Dal-1, Aba-6, 
Val-9, and Ala-11). It has a cyclic backbone, as indicated by the black line connecting the last 
residue to the first. Based on reported structures, the peptide bond between Mle-2 and Mle-3 can 
adopt either a cis or trans conformations. Structures of cyclosporin A bound to a protein target 
(typically cyclophilin) are similar (blue, only backbone shown for clarity; top left), and have the 
Mle-3 bond in the trans orientation. We have chosen one of these to represent the 'open' 
conformation. In chloroform, cyclosporin A adopts an extended conformation (orange) in 
chloroform, in which the Mle-3 bond adopts a cis orientation. We refer to this structure as the 
'closed' conformation. A schematic of a lipid bilayer is shown to highlight the overall focus of 
the manuscript on membrane permeability. 
 
Figure 2. Dynamics of cyclosporin A characterized by NMR. a) 1H 1D NMR spectra of 
cyclosporin A in various solvents, including aqueous mixtures of deuterated acetonitrile and 
water (38–100% v/v CD3CN), and pure deuterated chloroform (CDCl3). The sample temperature 
as well as the solvent composition is shown to the left of each spectrum. The four backbone 
amides of cyclosporin A are labelled. The asterisk indicates the solvent peak. b) 13C Spin-lattice 
(T1) and heteronuclear NOE (hNOE) values recorded at 500, 600, and 900 MHz in CDCl3 at 298 
K, and were used to derive generalized order parameters (S2) from a model-free analysis. The 
sequence of the cyclosporin A is shown for reference. 
 
Figure 3. Molecular dynamics simulations of the closed structure in chloroform. 
Simulations in explicit chloroform were carried out using the closed structure as the starting 
point. a) Root mean squared deviation (RMSD; backbone heavy atoms) of simulated structures 
compared to the closed structure at 298, 315, and 490 K. b) The conformations at two time-
points in the 490 K simulation, labelled with (i) and (ii), are shown, along with the RMSD 
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values. c) Average order parameters ‹S2› were calculated from the simulations and compared to 
that from the nuclear spin relaxation (NSR) analysis (Figure 2). 
 
Figure 4. Molecular dynamics simulations of the open structure in chloroform. Simulations 
in explicit chloroform were carried out using the open structure as the starting point. a) Root 
mean squared deviation (RMSD; backbone heavy atoms) of simulated structures compared to the 
closed structure at 315 and 490 K. The structure at the (i) time-point (green) is aligned to the 
closed structure (orange).  The Mle-3 peptide bond adopts a trans orientation, whereas the same 
bond adopts a cis orientation in the closed structure. b) Adaptive biasing force calculations of 
amino acids capped at both terminal ends (Ac-X-NH2). The key shows the tested identities of X 
(using a three-letter code) and the time length of the calculations, as well as the percentage 
modification to the force constants acting on the ω dihedral angles of N-methylated amino acids. 
c) Simulations of the open form at 490 K, using the 80% and 60% force field (FF) modifications 
to the force constants. The RMSD compared to the closed form is shown, along with the Mle-3 ω 
angle. The structure at the (ii) time-point (green) aligns well with the closed structure (orange), 
with a RMSD of 0.73 Å. d) Further simulations at different temperatures; i.e., 315, 393, and 
448K. A simulation at 490 K with the 60% modification to the force constants applied only to 
the Mle-3 ω angle was also executed. 
 
Figure 5. Molecular dynamics simulations of cyclosporin A in water. Starting with either the 
closed form (orange) or the open form (blue), simulations in an explicit water box were 
conducted at 315 and 490 K. a) In the upper panel, the root mean squared deviation (RMSD; 
backbone heavy atoms) of simulated structures compared to the closed structure for each 
simulation are shown as box plots. In the lower panel, the Mle-3 ω angle over the course of each 
simulation is shown in box plots. The angle corresponding to the ideal cis and trans bond 
orientations is shown for reference. The result for the simulation of the closed form in 
chloroform (CHCl3) at 315 K is also shown for comparison. b) In the upper panel, the solvent-
accessible surface area (SASA) for each simulation as box plots. In the lower panel, the polar 
surface area (PSA) distribution for the backbone polar groups of the simulated structures are 
shown. 
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Figure 6. In silico partitioning of cyclosporin A between water and chloroform. Simulations 
of cyclosporin A were conducted in a water–chloroform biphasic system at 490 K, and with the 
force constants modified to 60% of their original values (60% FF). a) The position of 
cyclosporin A relative to the membrane normal over the course of the simulation is shown. The 
root mean squared deviation (RMSD; backbone heavy atoms) of simulated structures compared 
to the closed structure is also plotted. An illustration of the simulation box is shown (top right). 
b) Box plots of the position of cyclosporin A along the chloroform normal for simulations in 
which cyclosporin A was not constrained, constrained in the closed conformation, and 
constrained in the open conformation. The grey shaded region corresponds to the chloroform 
phase of the simulation box. 
 
Figure 7. NMR structural studies of cyclosporin A in membrane mimics. a) Chemical 
structures of chloroform and membrane mimics, including cyclohexane, SDS, and DPC. The 
chemical structure of POPC is also illustrated for comparison. The Hα chemical shifts of 
cyclosporin A in chloroform, cyclohexane, and DPC are shown. The chemical shifts of 
cyclosporin A in SDS were obtained from a previous report.29 Below this plot is the Hα  
chemical shifts of cyclosporin A in cyclohexane, SDS and DPC, relative to those in chlorofom 
(secondary shifts). b) 1D 1H spectra of cyclosporin A in cyclohexane and in the presence of DPC 
(and water). The temperature of the samples are shown, as well as the cyclosporin A to DPC 
ratio (w/w), where relevant. The peaks of the main conformation corresponding to the four 
backbone amides of cyclosporin A are labelled. 
 
Figure 8. Membrane permeability of cyclosporin A in silico. Cyclosporin A was simulated in 
cyclohexane and in the presence of a POPC lipid bilayer with the 60% force constant 
modification (60% FF). a) The open structure was simulated in a box of explicit cyclohexane at 
315, 393, 448, and 490 K. The root mean squared deviation (RMSD) of simulated structures 
compared to the closed structure is plotted. b) Position of cyclosporin A relative to the 
membrane normal and the root mean squared deviation (RMSD; backbone heavy atoms) of 
simulated structures (after equilibration) compared to the closed structure are plotted. To the 
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right is an illustration of the simulation box, showing that it is composed of a lipid bilayer. At the 
start of the simulation, cyclosporin A is placed above the lipid bilayer. c) Box plot of the RMSD 
dependence on exposure to water over the whole simulation. d) Simulations at 315, 393, and 
490K. e) Area per lipid depending on the simulation temperature. f) Box plots of the position of 
cyclosporin A along the membrane normal for simulations (20–250 ns period of the production 
runs) in which cyclosporin A was not constrained, constrained in the closed conformation, and 
constrained in the open conformation. The grey shaded region corresponds to the lipid bilayer of 
the simulation box. 
 
Figure 9. Membrane permeability of cyclosporin H and cyclic hexapeptides in silico. a) The 
sequence of cyclosporin H is shown at the top, with each residue represented using a three-letter 
code. The residue in bold at position 4 distinguishes cyclosporin H from cyclosporin A (i.e. Dmv 
instead of Mva). Below the sequence are 1H 1D NMR spectra at 298K of cyclosporin H in 
various solvents, including a mixture of methanol and water (50% v/v methanol-d), acetonitrile 
and water (50% v/v acetonitrile-d3), pure chloroform (chloroform-d), pure cyclohexane 
(cyclohexane-d12), and in the presence of DPC micelles (at 1:100 and 1:250 peptide:DPC 
ratios). The solvent composition is shown above each spectrum. To the right is the backbone 
structure of cyclosporin H determined from crystals grown from methanol.42 b) The sequence of 
two cyclic hexapeptides referred to as cyclic peptide 1 and 13.16 (Cyclic peptide 1 was first 
reported as peptide 424). Cyclic peptide 13 differs from cyclic peptide 1 in that it the first two 
amino acids (highlighted in bold) have methylated amides. To the right is the backbone structure 
of cyclic peptide 13 in 30% acetonitrile16 with the two N-methylated residues labeled. c) Position 
of cyclosporin H relative to the membrane normal with no constraints on the backbone and with 
the backbone constrained to the starting conformation;42 the position of the lipid bilayer is 
shaded grey. At the start of the simulation, cyclosporin H is placed above the lipid bilayer and 
simulated with the 60% force constant modification (60% FF). On the right is are box plots of 
the position of cyclosporin H, and cyclic peptide 1 and 13, along the membrane normal for 
simulations in which the peptide was not constrained or constrained as indicated below the plots. 
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Figure 10. Role of conformational polymorphism in membrane permeability of cyclosporin 
A. Outside of the membrane, cyclosporin A samples multiple different conformations, as 
indicated by the differently colored shapes. During permeation, it is likely that multiple states are 
sampled, with the proportion of each state changing depending on the phase (i.e. aqueous, 
membrane head group, membrane tail). In other words, it is likely that multiple permeation 
pathways exist, characterized by different combination of states at each phase. Each state has 
different physiochemical properties that affect its transition to the next phase; for example, the 
size of the solvation shell or the area of the open hydrophobic surface. Each state also interacts 
with the membrane differently, with some more able to negotiate through the polymeric net 
formed by the lipids. 
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